Kuros Biosciences

Kuros Biosciences is pleased to report financial results for the first half of 2024 which have shown an extraordinary 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝗼𝗳 𝟭𝟱𝟵% 𝗶𝗻 𝗱𝗶𝗿𝗲𝗰𝘁 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀ᵀᴹ 𝘀𝗮𝗹𝗲𝘀 from H1 2023.   Financial highlights also include significant increases in total Kuros medical device segment sales, EBITDA, cash and cash equivalents.   In addition to impressive financial highlights, 𝗞𝘂𝗿𝗼𝘀 𝗵𝗮𝗱 𝘀𝗲𝘃𝗲𝗿𝗮𝗹 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆, 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹, 𝗮𝗻𝗱 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗮𝗰𝗵𝗶𝗲𝘃𝗲𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝗛𝟭 𝟮𝟬𝟮𝟰 including Level 1 human clinical study outcomes published in Spine, new FDA clearances, and the launch of MagnetOs Granules and MagnetOs Putty in New Zealand.   Chris Fair, Chief Executive Officer of Kuros Biosciences, stated: “We are pleased to report first half 2024 results that continue to demonstrate our strong execution and commercialization, with direct MagnetOs revenue growth of 159% fueling the MagnetOs EBITDA margin of 27% and total Kuros Group EBITDA margin of 2%, adjusted at 12.5%. Our growing body of clinical evidence, including our recently published MAXA Level 1 clinical study in the peer-reviewed journal Spine, demonstrates how our differentiated technology continues to surpass expectations in providing compared to autograft a superior bone healing solution to surgeons and patients. With additional clearances from the FDA and other regulatory bodies currently applied for, we look forward to driving steady penetration of MagnetOs in the musculoskeletal biologics market.”   To read the full press release, click here → https://lnkd.in/eynjsYTm

OK, 𝙘𝙖𝙧𝙙𝙨 𝙤𝙣 𝙩𝙝𝙚 𝙩𝙖𝙗𝙡𝙚… There’s a lot we could say about the four MagnetOs™ bone grafts now FDA-cleared for interbody procedures. * But sometimes it’s best to just let the surgeon’s hands do the talking. Watch this one-minute POV video of a PLF and TLIF being performed with MagnetOs Flex Matrix → https://lnkd.in/edd-VBBV

It makes sense that you want to be holding 𝙖𝙡𝙡 𝙩𝙝𝙚 𝙘𝙖𝙧𝙙𝙨 when choosing a bone graft for interbody procedures. * So, what exactly can our MagnetOs™ product family help you achieve now that 𝗮𝗹𝗹 𝗳𝗼𝘂𝗿 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀 𝗮𝗿𝗲 𝗙𝗗𝗔-𝗰𝗹𝗲𝗮𝗿𝗲𝗱 𝗳𝗼𝗿 𝗶𝗻𝘁𝗲𝗿𝗯𝗼𝗱𝘆 𝘂𝘀𝗲? * • If you want a ready-to-use, easy-to-mold product that’s designed to stay put, and available for standalone use, try 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝗘𝗮𝘀𝘆𝗽𝗮𝗰𝗸 𝗣𝘂𝘁𝘁𝘆. ¹˒² • For a bone graft that stays strong yet flexible even when hydrated with BMA, look no further than 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝗙𝗹𝗲𝘅 𝗠𝗮𝘁𝗿𝗶𝘅. ³ • If you prefer a standalone bone graft for performing interbody procedures, we offer 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝗣𝘂𝘁𝘁𝘆. ⁴ • Or you can use 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝗚𝗿𝗮𝗻𝘂𝗹𝗲𝘀 in interbody procedures when hydrated with blood. ⁵ If you want to know which MagnetOs product best meets the unique needs of you and your patient, schedule a Meet the Expert session today → https://lnkd.in/eZpMrvqB

How are we 𝗿𝗮𝗶𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝘀𝘁𝗮𝗸𝗲𝘀 in spinal fusion technology? In addition to the FDA having cleared all four MagnetOs™ bone grafts for use in the interbody space*, we continue to value research from leading surgeons demonstrating their experiences with MagnetOs in interbody procedures. In a retrospective clinical study, 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝗮𝗰𝗵𝗶𝗲𝘃𝗲𝗱 𝟵𝟰.𝟮% 𝗳𝘂𝘀𝗶𝗼𝗻 𝗶𝗻 𝗹𝘂𝗺𝗯𝗮𝗿 𝗶𝗻𝘁𝗲𝗿𝗯𝗼𝗱𝘆 𝗰𝗮𝘀𝗲𝘀 (49 of 52 patients). ¹ To read the retrospective clinical study, click here → https://lnkd.in/ekudkN3x

Human data consistently 𝗮𝗰𝗲𝘀 animal data when it comes to assessing bone graft substitutes. Which is why MagnetOs™ products cleared for use in the interbody space are underpinned by human clinical studies. * A recently published independent clinical study involving 63 patients who underwent 1-3 level ALIFs and LLIFs using 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝗣𝘂𝘁𝘁𝘆 𝘀𝗵𝗼𝘄𝗲𝗱 𝗮𝗻 𝟴𝟲% 𝗳𝘂𝘀𝗶𝗼𝗻 𝗿𝗮𝘁𝗲 𝗮𝘁 𝟭𝟮 𝗺𝗼𝗻𝘁𝗵𝘀 (or 90% of levels). ¹ Importantly, this included 𝟒𝟗% 𝐨𝐟 𝐬𝐭𝐮𝐝𝐲 𝐬𝐮𝐛𝐣𝐞𝐜𝐭𝐬 𝐢𝐧 𝐚 𝐡𝐢𝐠𝐡-𝐫𝐢𝐬𝐤 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐜𝐨𝐡𝐨𝐫𝐭. 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗶𝗻𝘃𝗲𝘀𝘁𝗶𝗴𝗮𝘁𝗼𝗿-𝗶𝗻𝗶𝘁𝗶𝗮𝘁𝗲𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝘁𝘂𝗱𝘆 𝗵𝗲𝗿𝗲 → https://lnkd.in/e6jc3mb8

All four MagnetOs™ bone grafts are now FDA-cleared for use in the interbody space. * But did you know that we have another 𝗮𝗰𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗵𝗼𝗹𝗲 when it comes to supporting surgeons? In PLF - one of the most challenging spinal fusion procedures - MagnetOs achieved 𝗻𝗲𝗮𝗿𝗹𝘆 𝘁𝘄𝗶𝗰𝗲 𝘁𝗵𝗲 𝗳𝘂𝘀𝗶𝗼𝗻 𝗿𝗮𝘁𝗲 of autograft in the latest level 1 human clinical trial (𝟳𝟵% 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝘃𝘀. 𝟰𝟳% 𝗮𝘂𝘁𝗼𝗴𝗿𝗮𝗳𝘁). ¹⁻³ And results are now available for your review in Spine. ⁴ 𝗚𝗲𝘁 𝗿𝗲𝗮𝗱𝘆 𝗳𝗼𝗿 𝗮𝗻 𝗮𝗹𝗹-𝗶𝗻 𝘀𝗵𝗼𝘄𝗱𝗼𝘄𝗻! To learn more information about MagnetOs and this level 1 study, meet with one of our experts → https://lnkd.in/eZpMrvqB

Whenever you see MagnetOs™ on the label, you can be confident that your bone graft is FDA cleared for: • 𝗖𝗲𝗿𝘃𝗶𝗰𝗮𝗹, 𝘁𝗵𝗼𝗿𝗮𝗰𝗶𝗰 𝗮𝗻𝗱 𝗹𝘂𝗺𝗯𝗮𝗿 𝗶𝗻𝘁𝗲𝗿𝗯𝗼𝗱𝘆 𝗽𝗿𝗼𝗰𝗲𝗱𝘂𝗿𝗲𝘀* • 𝗣𝗿𝗲-𝗮𝗻𝗱-𝗽𝗼𝘀𝘁 𝗳𝗶𝗹𝗹 𝗶𝗻𝘁𝗲𝗿𝗯𝗼𝗱𝘆 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀. • 𝗣𝗟𝗙 𝗽𝗿𝗼𝗰𝗲𝗱𝘂𝗿𝗲𝘀. ¹⁻⁴ Arrange a Meet the Expert session today to learn how to optimize your interbody procedures with MagnetOs and meet your patients' surgical needs → https://lnkd.in/eZpMrvqB

Are you striving for a 𝗺𝗼𝗿𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝘀𝗽𝗶𝗻𝗮𝗹 𝗳𝘂𝘀𝗶𝗼𝗻? The unique NeedleGrip™ surface technology of MagnetOs™ enables bone formation without added cells or growth factors. ¹˒²˒†˒‡ P-15 Peptide bone grafts have not demonstrated the same ability. ³⁻⁶˒† Learn what leading surgeons have to say about their experiences using MagnetOs  → https://lnkd.in/gG4uKwuW Read about the science behind MagnetOs and our NeedleGrip surface technology  → https://lnkd.in/e5GvEf5s

Are you a surgeon concerned about 𝗯𝗼𝗻𝗲 𝗴𝗿𝗮𝗳𝘁 𝗺𝗶𝗴𝗿𝗮𝘁𝗶𝗼𝗻? 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀ᵀᴹ 𝗶𝘀 𝗮 𝗯𝗼𝗻𝗲 𝗴𝗿𝗮𝗳𝘁 𝘁𝗵𝗮𝘁 𝗶𝘀 𝗽𝗿𝗼𝘃𝗲𝗻 𝘁𝗼 𝘀𝘁𝗮𝘆 𝗽𝘂𝘁 - with no mixing required. ¹ However, inadequate containment of water-soluble carriers like those found in P-15 Peptide grafts could result in product migration from the intended implantation site. ² MagnetOs sticks where you place it – in all putty formulations. Discover how → https://lnkd.in/e5GvEf5s

Are all bone grafts equal? 𝗬𝗼𝘂 𝗯𝗲 𝘁𝗵𝗲 𝗷𝘂𝗱𝗴𝗲… All MagnetOs™ formulations are cleared for use in both PLF (with level 1 data to support bone growth); and in any interbody space (cervical, thoracic, lumbar). * Unlike P-15 Peptides, which are currently only approved in the United States for single-level ACDF – a procedure recognized as having high fusion rates. ¹ 𝗦𝘁𝗮𝘆 𝗼𝗻 𝗹𝗮𝗯𝗲𝗹 𝘄𝗶𝘁𝗵 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀. Click here to view the results from our latest level 1 human clinical trial ² → https://lnkd.in/gdv5tnhQ To learn more about Project Fusion, click here → https://lnkd.in/gRajBqC7